milvexian

factor XIa inhibitor

Also Known As:

(9R,13S)-13-(4-(5-chloro-2-(4-chlorotriazol-1-yl)phenyl)-6-oxopyrimidin-1-yl)-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo(12.3.1.02,6)octadeca-1(18),2(6),4,14,16-pentaen-8-one; BMS-986177; JNJ-70033093

Networked: 8 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - milvexian: 8
  - Pyrimidines: 510
    - milvexian: 8

Experts

1.	Li, Danshi: 2 articles (01/2022 - 01/2022)
2.	Perera, Vidya: 2 articles (01/2022 - 01/2022)
3.	Wang, Zhaoqing: 2 articles (01/2022 - 01/2022)
4.	Abelian, Grigor: 1 article (01/2022)
5.	Bello, Akintunde: 1 article (01/2022)
6.	Bozarth, Jeffrey M: 1 article (01/2022)
7.	Cerra, Michael: 1 article (01/2022)
8.	Chen, Wei: 1 article (01/2022)
9.	Crain, Earl J: 1 article (01/2022)
10.	DeSouza, Mary: 1 article (01/2022)

Related Diseases

1.	Hemorrhage 10/01/2022 - "Milvexian was well tolerated, with no deaths, serious adverse events, or serious bleeding reported. " 01/01/2022 - "Single doses of milvexian 60 mg were generally well tolerated, with no serious adverse events (AEs), bleeding AEs, or discontinuations due to AEs. " 01/01/2022 - "All milvexian dosing regimens were safe and well-tolerated, with only mild treatment-emergent adverse events and no clinically significant bleeding events. " 12/02/2021 - "Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively. " 12/02/2021 - "Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. "
2.	Venous Thromboembolism 12/02/2021 - "The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). " 12/02/2021 - "Milvexian for the Prevention of Venous Thromboembolism." 12/02/2021 - "Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. " 12/02/2021 - "Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. "
3.	Thrombosis (Thrombus) 07/14/2023 - "This review focuses on a discussion of the potential clinical benefits of small molecule FXIa inhibitors, mainly asundexian and milvexian, in arterial thrombosis based on their pharmacological profiles and the compelling results of phase 2 clinical studies. " 01/01/2022 - "For prevention, milvexian 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 mg/kg+mg/kg/h preserved 32 ± 6, 54 ± 10, and 76 ± 5%* of carotid blood flow (CBF) and reduced thrombus weight by 15 ± 10, 45 ± 2, and 70 ± 4%, respectively (p < .05; n = 6/dose). " 01/01/2022 - "Milvexian was evaluated for in vivo prevention and treatment of thrombosis. " 01/01/2022 - "Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits." 01/01/2022 - "In vitro properties of milvexian were evaluated with coagulation and enzyme assays, and in vivo profiles were characterized with rabbit models of electrolytic-induced carotid arterial thrombosis and cuticle bleeding time (BT). "
4.	Ischemic Stroke 10/01/2022 - "The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA." 10/01/2022 - "Participants (N = 2366) with ischemic stroke (National Institutes of Health Stroke Scale score ≤7) or high-risk TIA (ABCD2 score ≥6) were randomized to 1 of 5 doses of milvexian or placebo for 90 days. " 07/14/2023 - "Therefore, FXIa inhibitors might represent a new class of direct-acting oral anticoagulants (DOACs) for the treatment of thrombosis, although the explicit clinical positions of asundexian and milvexian in patients with ischemic stroke, high-risk TIA, and coronary artery disease require confirmation from the outcomes of ongoing phase 3 trials."
5.	Coronary Artery Disease (Coronary Atherosclerosis) 07/14/2023 - "Therefore, FXIa inhibitors might represent a new class of direct-acting oral anticoagulants (DOACs) for the treatment of thrombosis, although the explicit clinical positions of asundexian and milvexian in patients with ischemic stroke, high-risk TIA, and coronary artery disease require confirmation from the outcomes of ongoing phase 3 trials."

Related Drugs and Biologics

1.	Factor XIa (Coagulation Factor XIa)
2.	Factor Xa Inhibitors
3.	Enoxaparin (Lovenox)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Enzymes
6.	Anticoagulants

Related Therapies and Procedures

1.	Knee Replacement Arthroplasty (Total Knee Replacement)